Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab Maintenance and Extension Study in Crohn's Disease
NCT03105102Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2018
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies
- Countries
- 47
01
Overview
A Phase 3 trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc.. Started Apr 2018; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03105102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105102.